{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T07:11:35Z","timestamp":1778483495285,"version":"3.51.4"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017686","name":"Fujian Provincial Health Technology Project","doi-asserted-by":"publisher","award":["2025CXB013"],"award-info":[{"award-number":["2025CXB013"]}],"id":[{"id":"10.13039\/501100017686","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2024J01539"],"award-info":[{"award-number":["2024J01539"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.critrevonc.2026.105306","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:19:44Z","timestamp":1774628384000},"page":"105306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Chemoimmunotherapy efficacy in patients with and without liver metastases: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"222","author":[{"given":"Salah Ameen","family":"Abdu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuad","family":"Al-Haddad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wafa Ali","family":"Asaad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maged Ali","family":"Al-Aroomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najm Aldain","family":"Ameen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tauqeer","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105306_bib1","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.4240\/wjgs.v16.i6.1513","article-title":"Immunotherapy in gastric cancer with liver metastasis: challenges and opportunities","volume":"16","author":"Bardak\u00e7i","year":"2024","journal-title":"World J. Gastrointest. Surg."},{"key":"10.1016\/j.critrevonc.2026.105306_bib2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B (Methodol.)"},{"key":"10.1016\/j.critrevonc.2026.105306_bib3","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105306_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol32090493","article-title":"Tumor immune microenvironment and current status of immune checkpoint inhibitor therapy in colorectal cancer liver metastasis","volume":"32","author":"Cao","year":"2025","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105306_bib5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41423-024-01245-8","article-title":"Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors","volume":"22","author":"Catanzaro","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105306_bib6","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1042\/CS20190654","article-title":"The immune niche of the liver","volume":"135","author":"Cheng","year":"2021","journal-title":"Clin. Sci."},{"key":"10.1016\/j.critrevonc.2026.105306_bib7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","article-title":"Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer","volume":"17","author":"Cheng","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105306_bib8","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.21037\/jgo-24-738","article-title":"Metastasis patterns and prognosis in patients with gastric cancer: a Surveillance, Epidemiology, and End Results-based analysis","volume":"15","author":"Dong","year":"2024","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105306_bib9","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s10120-024-01514-5","article-title":"Janus kinase inhibitor overcomes resistance to immune checkpoint inhibitor treatment in peritoneal dissemination of gastric cancer in C57BL\/6 J mice","volume":"27","author":"Du","year":"2024","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.critrevonc.2026.105306_bib10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41698-024-00630-w","article-title":"Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy","volume":"8","author":"Elkrief","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105306_bib11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/jrsm.1049","article-title":"Accounting for correlation in network meta-analysis with multi-arm trials","volume":"3","author":"Franchini","year":"2012","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.critrevonc.2026.105306_bib12","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3390\/cancers16101837","article-title":"Hepatocellular carcinoma and the multifaceted relationship with its microenvironment: attacking the hepatocellular carcinoma defensive fortress","volume":"16","author":"Galasso","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105306_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70476","article-title":"Immunotherapy with programmed cell death 1 versus programmed cell death ligand 1 inhibitors in patients with advanced non\u2013small cell lung cancers: a multicenter, retrospective analysis","volume":"6","author":"Gan","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.critrevonc.2026.105306_bib14","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105306_bib15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/jrsm.1590","article-title":"Estimating interactions and subgroup-specific treatment effects in meta-analysis without aggregation bias: a within-trial framework","volume":"14","author":"Godolphin","year":"2023","journal-title":"Res Synth. Methods"},{"key":"10.1016\/j.critrevonc.2026.105306_bib16","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41591-024-02823-z","article-title":"A gut microbial signature for combination immune checkpoint blockade across cancer types","volume":"30","author":"Gunjur","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105306_bib17","doi-asserted-by":"crossref","first-page":"180","DOI":"10.31635\/ccschem.024.202303793","article-title":"Cationic spherical polypeptides with immunogenic cell death inducing activity for oncolytic immunotherapy","volume":"7","author":"Guo","year":"2025","journal-title":"CCS Chem."},{"key":"10.1016\/j.critrevonc.2026.105306_bib18","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Bmj"},{"key":"10.1016\/j.critrevonc.2026.105306_bib19","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105306_bib20","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 Study","volume":"41","author":"Harrington","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105306_bib21","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1158\/2767-9764.CRC-25-0157","article-title":"Chemoimmunotherapy outcomes and prognostic factors in patients with advanced, low PD-L1\u2013expressing non\u2013small cell lung cancer","volume":"5","author":"Hata","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.critrevonc.2026.105306_bib22","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.critrevonc.2026.105306_bib23","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105306_bib24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/cmi.2015.112","article-title":"Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells","volume":"13","author":"Horst","year":"2016","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105306_bib25","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s12094-024-03565-7","article-title":"Comparison of the efficacy and safety of domestically produced tislelizumab, camrelizumab, and imported pembrolizumab in the treatment of advanced NSCLC: a real-world retrospective study","volume":"27","author":"Hu","year":"2025","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105306_bib26","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41417-025-00886-9","article-title":"MDSC checkpoint blockade therapy: a new breakthrough point overcoming immunosuppression in cancer immunotherapy","volume":"32","author":"Ibrahim","year":"2025","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.critrevonc.2026.105306_bib27","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00262-025-04125-w","article-title":"Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1\u2009<\u200950%: results from an Italian observational study","volume":"74","author":"Inno","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105306_bib28","doi-asserted-by":"crossref","first-page":"23231","DOI":"10.1038\/s41598-024-72697-1","article-title":"Induction of immunogenic cell death and enhancement of the radiation-induced immunogenicity by chrysin in melanoma cancer cells","volume":"14","author":"Jafari","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105306_bib29","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/imr.13301","article-title":"Decoding immunogenic cell death from a dendritic cell perspective","volume":"321","author":"Janssens","year":"2024","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.critrevonc.2026.105306_bib30","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1158\/1535-7163.MCT-24-0367","article-title":"Vitamin A metabolism and resistance of hepatic metastases to immunotherapy","volume":"24","author":"Jones","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105306_bib31","doi-asserted-by":"crossref","first-page":"eadt3044","DOI":"10.1126\/sciadv.adt3044","article-title":"PD-L1-CD80 interactions are required for intracellular signaling necessary for dendritic cell migration","volume":"11","author":"Kantheti","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.critrevonc.2026.105306_bib32","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/s41416-024-02704-9","article-title":"Why does circadian timing of administration matter for immune checkpoint inhibitors\u2019 efficacy?","volume":"131","author":"Karabou\u00e9","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105306_bib33","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105306_bib34","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.4049\/jimmunol.2300674","article-title":"Regulation of tumor dendritic cells by programmed cell death 1 pathways","volume":"212","author":"Knutson","year":"2024","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105306_bib35","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41423-025-01313-7","article-title":"Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells","volume":"22","author":"Kostallari","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105306_bib36","article-title":"Chemotherapy-induced immunogenic cell death in combination with ICIs: a brief review of mechanisms, clinical insights, and therapeutic implications","volume":"16","author":"Li","year":"2025","journal-title":"Front Pharm."},{"key":"10.1016\/j.critrevonc.2026.105306_bib37","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105306_bib38","doi-asserted-by":"crossref","first-page":"9561","DOI":"10.18632\/aging.205035","article-title":"Impact of liver metastases status on survival outcomes of first-line immunotherapy in extensive stage small cell lung cancer: a systematic review and meta-analysis","volume":"15","author":"Lin","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.critrevonc.2026.105306_bib39","first-page":"135","article-title":"Immunotherapeutic strategies in head and neck cancer: challenges and opportunities","author":"Liu","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.critrevonc.2026.105306_bib40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12964-025-02170-7","article-title":"The immunosuppressive role of MDSCs in HCC: mechanisms and therapeutic opportunities","volume":"23","author":"Liu","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.critrevonc.2026.105306_bib41","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1186\/s12913-014-0579-0","article-title":"PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews","volume":"14","author":"Methley","year":"2014","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.critrevonc.2026.105306_bib42","first-page":"630","article-title":"Comprehensive evaluation of PD-1 inhibitors marketed in China based on a Quick Guideline for drug evaluation and selection in Chinese Medical Institutions (second edition)","volume":"2","author":"Min","year":"2024","journal-title":"Intell. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105306_bib43","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.3748\/wjg.v17.i36.4067","article-title":"Current treatment for colorectal liver metastases","volume":"17","author":"Misiakos","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2026.105306_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103482","article-title":"Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1\/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis","volume":"88","author":"Oresti","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.critrevonc.2026.105306_bib45","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2026.105306_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122481","article-title":"Nanomedicines for reversing immunosuppressive microenvironment of hepatocellular carcinoma","volume":"306","author":"Pan","year":"2024","journal-title":"Biomaterials"},{"key":"10.1016\/j.critrevonc.2026.105306_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011310","article-title":"Hyperglycemia induces an immunosuppressive microenvironment in colorectal cancer liver metastases by recruiting peripheral blood monocytes through the CCL3-CCR1 axis","volume":"13","author":"Peng","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105306_bib48","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jtho.2024.05.376","article-title":"Benefit with no target: long-term outcomes of chemoimmunotherapy in 201c;PD-L1 negative 201d; NSCLC","volume":"19","author":"Perrone","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105306_bib49","doi-asserted-by":"crossref","first-page":"20027","DOI":"10.1038\/s41598-024-70208-w","article-title":"CT radiomics-based biomarkers can predict response to immunotherapy in hepatocellular carcinoma","volume":"14","author":"Qi","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105306_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102893","article-title":"The effect of liver metastasis on efficacy of immunotherapy plus chemotherapy in advanced lung cancer","volume":"147","author":"Qin","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105306_bib51","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-023-02482-w","article-title":"Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with liver metastases","volume":"130","author":"Qu","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105306_bib52","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.critrevonc.2026.105306_bib53","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial","volume":"17","author":"Ren","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105306_bib54","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12967-024-04937-x","article-title":"Tumor mutational burden predictability in head and neck squamous cell carcinoma patients treated with immunotherapy: systematic review and meta-analysis","volume":"22","author":"Rodrigo","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105306_bib55","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2016-08-731885","article-title":"Targeting the PD-1\/PD-L1 axis in multiple myeloma: a dream or a reality?","volume":"129","author":"Rosenblatt","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105306_bib56","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3390\/cancers17050906","article-title":"Targeting immune checkpoint inhibitors for non-small-cell lung cancer: beyond PD-1\/PD-L1 monoclonal antibodies","volume":"17","author":"Roussot","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105306_bib57","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.21037\/tlcr-24-198","article-title":"Clinical insights: five-year follow-up of KEYNOTE-189 trial outcomes and more","volume":"13","author":"Se","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105306_bib58","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2026.105306_bib59","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105306_bib60","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12943-025-02378-8","article-title":"The tumor microenvironment in hepatocellular carcinoma: mechanistic insights and therapeutic potential of traditional Chinese medicine","volume":"24","author":"Su","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105306_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009543","article-title":"Personalized neoantigen hydrogel vaccine combined with PD-1 and CTLA-4 double blockade elicits antitumor response in liver metastases by activating intratumoral CD8(+)CD69(+) T cells","volume":"12","author":"Tang","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105306_bib62","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1007\/s12672-025-03138-2","article-title":"Natural killer cell therapy in hepatocellular carcinoma: a comprehensive review","volume":"16","author":"Tavakoli","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105306_bib63","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10585-023-10217-7","article-title":"Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis","volume":"40","author":"Tian","year":"2023","journal-title":"Clin. Exp. Metastas."},{"key":"10.1016\/j.critrevonc.2026.105306_bib64","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1001\/jamaoncol.2023.6277","article-title":"Immunotherapy or chemoimmunotherapy in older adults with advanced non\u2013small cell lung cancer","volume":"10","author":"Tsukita","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105306_bib65","doi-asserted-by":"crossref","DOI":"10.1111\/crj.70107","article-title":"Comprehensive analysis of lung cancer metastasis: sites, rates, survival, and risk factors-a systematic review and meta-analysis","volume":"19","author":"Wang","year":"2025","journal-title":"Clin. Respir. J."},{"key":"10.1016\/j.critrevonc.2026.105306_bib66","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.annonc.2024.03.007","article-title":"Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities","volume":"35","author":"Wang","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105306_bib67","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/s41416-022-02084-y","article-title":"Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy","volume":"128","author":"Wang","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105306_bib68","doi-asserted-by":"crossref","first-page":"8637","DOI":"10.1038\/s41598-025-90136-7","article-title":"Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product","volume":"15","author":"Willoughby","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105306_bib69","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","article-title":"Inhibitors of immune checkpoints\u2014PD-1, PD-L1, CTLA-4\u2014new opportunities for cancer patients and a new challenge for internists and general practitioners","volume":"40","author":"Wojtukiewicz","year":"2021","journal-title":"Cancer Metastas-.-. Rev."},{"key":"10.1016\/j.critrevonc.2026.105306_bib70","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105306_bib71","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study","volume":"24","author":"Xu","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105306_bib72","doi-asserted-by":"crossref","first-page":"859","DOI":"10.21037\/jtd-24-1495","article-title":"Comparison of camrelizumab, pembrolizumab, tislelizumab, and sintilimab as first-line treatment in patients with non-small cell lung cancer: a retrospective study","volume":"17","author":"Yan","year":"2025","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.critrevonc.2026.105306_bib73","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.trecan.2024.03.008","article-title":"Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development","volume":"10","author":"Yasuda","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2026.105306_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104750","article-title":"Regulation of the CD8\u207a T cell and PDL1\/PD1 axis in gastric cancer: Unraveling the molecular landscape","volume":"212","author":"Yong","year":"2025","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"10.1016\/j.critrevonc.2026.105306_bib75","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2528109","article-title":"Mature tertiary lymphoid structures linked to HPV status and anti-PD-1 based chemoimmunotherapy response in head and neck squamous cell carcinoma","volume":"14","author":"Zhang","year":"2025","journal-title":"OncoImmunology"},{"key":"10.1016\/j.critrevonc.2026.105306_bib76","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s12935-024-03484-1","article-title":"Locoregional therapies combined with immune checkpoint inhibitors for liver metastases","volume":"24","author":"Zhang","year":"2024","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.critrevonc.2026.105306_bib77","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41698-024-00759-8","article-title":"Methylation cytometric pretreatment blood immune profiles with tumor mutation burden as prognostic indicators for survival outcomes in head and neck cancer patients on anti-PD-1 therapy","volume":"8","author":"Zhang","year":"2024","journal-title":"npj Precis. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:35:13Z","timestamp":1778481313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":77,"alternative-id":["S1040842826001939"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105306","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemoimmunotherapy efficacy in patients with and without liver metastases: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105306","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105306"}}